ArticleNature cardiovascular research2022
Syndecan-2 selectively regulates VEGF-induced vascular permeability.
Article in Nature cardiovascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- CRISPR activation screens identify core protein-dependent regulation of heparan sulfate sulfation and ligand specificity.bioRxiv : the preprint server for biology · 2026Article
- The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy.Blood advances · 2026Article
- A study on the correlation between DNA methylation and protein expression levels ofThe Journal of international medical research · 2026Article
- The Role of the Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 in Breast Cancer Pathophysiology.Cells · 2025Article
- Activin A Prevents Hyperresponsiveness to Vascular Endothelial Growth Factor in Pathologic Blood Vessels by Perturbing the Trafficking of Activated Vascular Endothelial Growth Factor Receptor 2.The American journal of pathology · 2025Article
- VEGF-E Attenuates Injury After Ischemic Stroke by Promoting Reparative Revascularization.The European journal of neuroscience · 2025Article
- Genome-wide by trait interaction analyses with neuroticism reveal chronic pain-associated depression as a distinct genetic subtype.Translational psychiatry · 2025Article
- Endothelial transcriptomic, epigenomic and proteomic data challenge the proposed role for TSAd in vascular permeability.Angiogenesis · 2025Article
- CPHNet: a novel pipeline for anti-HAPE drug screening via deep learning-based Cell Painting scoring.Respiratory research · 2025Article
- Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV.Translational vision science & technology · 2025Article
- Syndecans modulate ghrelin receptor signaling.Journal of molecular endocrinology · 2025Article
- Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions.Angiogenesis · 2024Article
- Syndecans in hematopoietic cells and their niches.American journal of physiology. Cell physiology · 2024Review
- A Nucleic Acid-Based LYTAC Plus Platform to Simultaneously Mediate Disease-Driven Protein Downregulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Report from the 2023 workshop on endothelial permeability, edema and inflammation.Nature cardiovascular research · 2023Article
- Global impact of proteoglycan science on human diseases.iScience · 2023Review
- Biology and therapeutic targeting of vascular endothelial growth factor A.Nature reviews. Molecular cell biology · 2023Review
- Activin A Limits VEGF-Induced Permeability via VE-PTP.International journal of molecular sciences · 2023Article
- KIF13B mediates VEGFR2 recycling to modulate vascular permeability.Cellular and molecular life sciences : CMLS · 2023Article
- Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate.Frontiers in immunology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Vascular endothelial growth factor (VEGF)- driven increase in vascular permeability is a key feature of many disease states associated with inflammation and ischemic injury, contributing significantly to morbidity and mortality in these settings. Despite its importance, no specific regulators that preferentially control VEGF-dependent increase in permeability versus its other biological activities, have been identified. Here we report that a proteoglycan Syndecan-2 (Sdc2) regulates the interaction between a transmembrane phosphatase DEP1 and VEGFR2 by controlling cell surface levels of DEP1. In the absence of Sdc2 or the presence of an antibody that blocks Sdc2-DEP1 interaction, increased plasma membrane DEP1 levels promote selective dephosphorylation of the VEGFR2 Y951 site that is involved in permeability control. Either an endothelial-specific Sdc2 deletion or a treatment with an anti-Sdc2 antibody result in a highly significant reduction in stroke size due to a decrease in intracerebral edema.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.